Kosuke Iwatani

Minato, 1058471, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 118 publications

Stage-specific prognostic impact and recurrence patterns according to tumor location in upper tract urothelial carcinoma following radical nephroureterectomy: a propensity score-matched analysis.

Stage-specific prognostic impact and recurrence patterns according to tumor location in upper tract urothelial carcinoma following radical nephroureterectomy: a propensity score-matched analysis.

Journal: Japanese journal of clinical oncology

Published: July 17, 2026

Real-world evaluation of primary prophylactic use of granulocyte colony-stimulating factor in patients with metastatic castration-sensitive prostate cancer treated with triplet therapy.

Real-world evaluation of primary prophylactic use of granulocyte colony-stimulating factor in patients with metastatic castration-sensitive prostate cancer treated with triplet therapy.

Journal: International journal of clinical oncology

Published: April 29, 2026

Rapidly Progressive Retroperitoneal Dissemination of Plasmacytoid Urothelial Carcinoma Presenting With Multiorgan Obstruction After Radical Cystectomy: A Case Report.

Rapidly Progressive Retroperitoneal Dissemination of Plasmacytoid Urothelial Carcinoma Presenting With Multiorgan Obstruction After Radical Cystectomy: A Case Report.

Journal: IJU case reports

Published: April 20, 2026

Consensus-Based Development of a Surgical Checklist for Transurethral Resection of Bladder Tumor: An Initiative of the Japanese Society of Urologic Oncology.

Consensus-Based Development of a Surgical Checklist for Transurethral Resection of Bladder Tumor: An Initiative of the Japanese Society of Urologic Oncology.

Journal: International journal of urology : official journal of the Japanese Urological Association

Published: April 01, 2026

Complete response after enfortumab vedotin plus pembrolizumab for a contralateral ureteral tumor in a solitary kidney after nephroureterectomy.

Complete response after enfortumab vedotin plus pembrolizumab for a contralateral ureteral tumor in a solitary kidney after nephroureterectomy.

Journal: International cancer conference journal

Published: March 31, 2026

Real-world safety and effectiveness of enfortumab vedotin plus pembrolizumab in locally advanced or metastatic urothelial carcinoma: A multicenter Japanese cohort study.

Real-world safety and effectiveness of enfortumab vedotin plus pembrolizumab in locally advanced or metastatic urothelial carcinoma: A multicenter Japanese cohort study.

Journal: Urologic oncology

Published: March 30, 2026

Prognostic impact of large cribriform architecture and intraductal carcinoma of the prostate in diagnostic biopsies of mCSPC receiving ARPI-based therapy.

Prognostic impact of large cribriform architecture and intraductal carcinoma of the prostate in diagnostic biopsies of mCSPC receiving ARPI-based therapy.

Journal: Japanese journal of clinical oncology

Published: February 02, 2026

Clinical Characteristics and Predictive Factors of Symptomatic Skeletal Events in Patients With Metastatic Castration-Sensitive Prostate Cancer Treated With Denosumab.

Clinical Characteristics and Predictive Factors of Symptomatic Skeletal Events in Patients With Metastatic Castration-Sensitive Prostate Cancer Treated With Denosumab.

Journal: Clinical genitourinary cancer

Published: December 30, 2025

Assessment of Circulating Neuroendocrine Tumor Markers at Prostate Cancer Diagnosis: An Investigation of Prostate Cancer With Neuroendocrine Features.

Assessment of Circulating Neuroendocrine Tumor Markers at Prostate Cancer Diagnosis: An Investigation of Prostate Cancer With Neuroendocrine Features.

Journal: The Prostate

Published: December 11, 2025

Tumor cell invasion of blood vessels predicts poor survival in upper tract urothelial carcinoma following radical nephroureterectomy.

Tumor cell invasion of blood vessels predicts poor survival in upper tract urothelial carcinoma following radical nephroureterectomy.

Journal: Japanese journal of clinical oncology

Published: December 11, 2025

Real-world comparison of enzalutamide and apalutamide in metastatic hormone-sensitive prostate cancer: a multi-institutional propensity score-matched analysis.

Real-world comparison of enzalutamide and apalutamide in metastatic hormone-sensitive prostate cancer: a multi-institutional propensity score-matched analysis.

Journal: Japanese journal of clinical oncology

Published: November 20, 2025

Prognostic impact of intraductal carcinoma of the prostate and PTEN loss in metastatic castration-sensitive prostate cancer treated with androgen receptor pathway inhibitors.

Prognostic impact of intraductal carcinoma of the prostate and PTEN loss in metastatic castration-sensitive prostate cancer treated with androgen receptor pathway inhibitors.

Journal: Japanese journal of clinical oncology

Published: November 07, 2025

Showing 1-12 of 118

Last Updated: 09/26/2026